Pfizer investors should participate in Zoetis spinoff, says BMO Capital

BMO Capital recommends that Pfizer (PFE) shareholders tender at least 50% of their shares in the Zoetis (ZTS) spinoff. The firm thinks that Zoetis has strong fundamental drivers and an attractive near-term risk/reward ratio. BMO keeps an Outperform rating on Pfizer.

View Comments (0)